HaleonMEX:HLNN 74 Pretax Margin % is 19.41% as of Dec. 2025, which is 21% above its 10-year median of 16.08. GuruFocus rates MEX:HLNN with a GF Score™ of 74/100 and a GF Value™ of MXN107.88. The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Haleon ranks better than 80.42% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Haleon's Pre-Tax Income for the
six
months ended in Dec. 2025 was MXN25,960 Mil. Haleon's Revenue for the
six
months ended in Dec. 2025 was MXN133,777 Mil. Therefore, Haleon's pretax margin for the quarter that ended in Dec. 2025 was 19.41%.
The historical rank and industry rank for Haleon's Pretax Margin % or its related term are showing as below:
MEX:HLNN'
s Pretax Margin % Range Over the Past 10 Years
Min: 10.45 Med: 16.08 Max: 19.51
Current: 19.51
MEX:HLNN's Pretax Margin % is ranked better than 80.42% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs MEX:HLNN: 19.51
Haleon (MEX:HLNN) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Haleon Pretax Margin % Related Terms
Haleon Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Haleon's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:HLNN vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleon Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haleon's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Haleon's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleon (MEX:HLNN) has a Pretax Margin % of 19.41% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Haleon and its competitors. This is 21% above median its historical median of 16.08. Over the past decade, Haleon's Pretax Margin % has ranged from 10.45 to 19.51. According to the industry distribution chart, Haleon ranks #187 out of 955 companies in the Drug Manufacturers industry, placing it in the top 19.6%.
Is Haleon's Pretax Margin % too high?
Haleon's current Pretax Margin % of 19.41% is 21% above median its 10-year median of 16.08. Over the past 10 years, this metric has ranged from a low of 10.45 to a high of 19.51. The Drug Manufacturers industry median Pretax Margin % is 7.28. Haleon's value of 19.41% is 166.6% above this industry median. Based on the distribution chart, Haleon ranks #187 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haleon has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Haleon's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Haleon ranks #187 out of 955 companies for Pretax Margin %. This places Haleon in the top 20% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Haleon's value of 19.41% is 166.6% above this benchmark. Historically, Haleon's own Pretax Margin % has ranged from 10.45 to 19.51 over the past decade. While the company's 10-year median is 16.08 vs. the industry median of 7.28, Haleon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haleon's current Pretax Margin % of 19.41% is 166.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Haleon and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haleon's current Pretax Margin % is 19.41%, which is 21% above median its own 10-year median of 16.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Haleon (MEX:HLNN) has a current Pretax Margin % of 19.41%. The stock's GF Value™ is MXN107.88, compared to a current price of MXN99.17 — trading 8.1% below its estimated fair value. The current Pretax Margin % is 19.41%, which is 21% above median its 10-year median of 16.08 and 166.6% above the Drug Manufacturers industry median of 7.28. Haleon's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Haleon (MEX:HLNN), the current Pretax Margin % is 19.41% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleon (MEX:HLNN) Overvalued in 2026?
Based on GuruFocus' analysis, Haleon stock appears to be undervalued.
The current stock price of MXN99.17 is trading 8.1% below its estimated GF Value™ of MXN107.88.
Key valuation signals for MEX:HLNN:
Pretax Margin %: 19.41% (21% above median its 10-year median of 16.08)
GF Value™: MXN107.88 vs. price of MXN99.17 (8.1% below fair value)
Industry Position: 166.6% above the Drug Manufacturers median (#187 of 955)
No single metric tells the full story. See the MEX:HLNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
74GF Score
Get the complete analysis for MEX:HLNN
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:HLNN has been successfully added to your 
